Ascension MCP Approval Should Not Include Postmarket Study Requirement
This article was originally published in The Gray Sheet
Executive Summary
Ascension Orthopedics' ten-year follow-up data on the Ascension MCP total metacarpophalangeal finger joint replacement obviates the need for a postmarket study, according to FDA's Orthopedics and Rehabilitation Devices Advisory Panel.